View Article

Abstract

A simple, precise, and reliable reverse-phase high-performance liquid chromatography (RP-HPLC) method was successfully developed and optimized for the simultaneous estimation of Dolutegravir and Rilpivirine in bulk and pharmaceutical dosage forms. Chromatographic separation was achieved using a YMC ODS C18 column with a mobile phase of phosphate buffer and methanol (35:65 v/v) at pH 3.5, yielding well-resolved peaks with satisfactory retention times and system suitability parameters. The method was validated according to ICH guidelines, demonstrating excellent linearity (10–50 µg/ml, correlation coefficients >0.999), precision (%RSD within acceptable limits), and accuracy (recovery close to 100%). Sensitivity was confirmed through low LOD and LOQ values. Robustness studies further established the reliability of the method. Overall, the developed RP-HPLC method is accurate, precise, linear, robust, and sensitive, making it suitable for routine quality control analysis of Dolutegravir and Rilpivirine in combined dosage forms. Its economical and time-efficient nature enhances applicability in pharmaceutical industries and research laboratories

Keywords

Dolutegravir; Rilpivirine; RP-HPLC; Method development; Validation; ICH guidelines; Simultaneous estimation; Quality control

Introduction

× Popup Image

Pharmaceutical analysis is an essential discipline within pharmaceutical sciences that ensures the identity, purity, safety, and efficacy of drug substances and pharmaceutical formulations. It encompasses a wide range of analytical techniques used throughout drug development, manufacturing, and quality control processes. The primary objective of pharmaceutical analysis is to guarantee that drugs meet predefined specifications and regulatory requirements. (1,2,3,5,6)

Importance of High-Performance Liquid Chromatography (HPLC)

High-Performance Liquid Chromatography (HPLC) is one of the most widely used analytical techniques for the separation, identification, and quantification of components in complex mixtures. It is especially valuable in pharmaceutical analysis due to its ability to handle thermally unstable, non-volatile, and high molecular weight compounds. (4,11,13,14)

HPLC offers several advantages, including: (4,13,14)

  • High resolution and selectivity
  • Rapid analysis with reproducible results
  • Capability to analyze multiple components simultaneously
  • High sensitivity for trace-level detection
  • Compatibility with a wide range of detectors

INTRODUCTION TO HPLC

HPLC is an advanced form of column chromatography that operates under high pressure to increase the efficiency and speed of the separation process. It has become a standard method for analyzing complex mixtures in various industries, particularly pharmaceuticals. (4,13,14)

Principles of HPLC: The principle of HPLC is based on the partitioning of components between a stationary phase (usually packed inside a column) and a mobile phase (solvent that moves through the column). The different affinities of each component for the stationary and mobile phases cause them to elute at different times, known as retention times. (4,14)

Types of HPLC:

  1. Normal Phase HPLC: Utilizes a polar stationary phase and a less polar mobile phase.
  2. Reverse Phase HPLC (RP-HPLC): The most common type, uses a non-polar stationary phase and a polar mobile phase.
  3. Ion Exchange HPLC: Separates ions and polar molecules based on their charge.
  4. Size Exclusion HPLC: Also known as gel permeation or gel filtration, separates molecules based on size.
  5. Affinity HPLC: Uses the specific interactions between one kind of solute molecule and a second molecule that is immobilized on a stationary phase. (4,11,13,14)

Applications of HPLC:

  1. Pharmaceuticals: Used for the analysis of active pharmaceutical ingredients (APIs), excipients, and formulations.
  2. Environmental Monitoring: Detects pollutants and contaminants in water, air, and soil.
  3. Food Industry: Analyzes food components for quality control and to ensure compliance with regulations.
  4. Clinical Research: Assists in the study of biological samples, such as plasma, for drug development and disease markers.
  5. Industrial Applications: Used in the production of chemicals and other materials to monitor process streams and ensure product purity.

HPLC is valued for its accuracy, precision, and ability to analyze a wide range of compounds. Its versatility makes it an indispensable tool in scientific research and quality control laboratories worldwide. (4,5,11,13)

System Suitability:  

According to the USP, system suitability tests are an integral part of chromatographic methods. These tests are used to verify that the resolution and reproducibility of the system are adequate for the analysis to be performed. System suitability tests are based on the concept that the equipment, electronics, analytical operations, and samples constitute an integral system that can be evaluated as a whole.  The purpose of the system suitability test is to ensure that the complete testing system (including instrument, reagents, columns, analysts) is suitable for the intended application. (9)

Similar to the analytical method development, the system suitability test strategy should be revised as the analysts develop more experience with the assay. (3,9)

System suitability is the checking of a system to ensure system performance before or during the analysis of unknowns. Parameters such as plate count, tailing factors, resolution and reproducibility (%RSD retention time and area for six repetitions) are determined and compared against the specifications set for the method. These parameters are measured during the analysis of system suitability "sample" that is a mixture of main components and expected by-products. Below Table lists the terms to be measured and their recommended limits obtained from the analysis of the system suitability sample as per current FDA guidelines on "Validation of Chromatographic Methods". (3,9)

 

Table 4. System Suitability Parameters and Recommendations

Parameter

Recommendation

Capacity Factor (k’)

The peak should be well-resolved from other peaks and the void volume, generally k’>2.0

Repeatability

RSD < 1% for N > 5 is desirable.

Relative retention

Not essential as long as the resolution is stated.

Resolution (Rs)

Rs of > 2 between the peak of interest and the closest eluting potential interferent (impurity, excipient, degradation product, internal standard, etc.

Tailing Factor (T)

T of < 2

Theoretical Plates (N)

N > 2000

 

 Accuracy: Defined as the closeness of agreement between the actual (true) value and mean analytical value obtained by applying the test method a number of times. Accuracy is acceptable if the difference between the true value and mean measured value does not exceed the RSD values obtained for repeatability of the method. (1,12)

Precision: It is a measure of degree of repeatability of an analytical method under normal operation and it is normally expressed as % of relative standard deviation (% RSD). This involves (1,12)

  1. Repeatability
  2. Reproducibility
  3.  Intermediate precision

                   % RSD = 100 S/X

Where,            S = Standard deviation

            X = Mean

 It is determined at three levels.

Linearity: It is the ability of the method to elicit test result that is directly proportional to analytic concentration within a given range. It is generally reported as variance of slope of regression line. It is determined by series of three to six injections of five of more standards. (1,12)

Limit of Detection (LOD): It is defined as the lowest concentration of an analyte in a sample that can be detected but not quantified. LOD is expressed as a concentration at a specified signal to noise ratio. The LOD will not only depend on the procedure of analysis but also on the type of instrument. (1,12)

In chromatography, detection limit is the injected amount that results in a peak with a height at least twice or thrice as high as baseline noise level.

S/N = 2/1 or 3/1

LOQ is expressed as a concentration at a specified signal to noise ratio. In chromatography, limit of quantification is the injected amount that results in a peak with a height, ten times as high as base line noise level.

S/N = 10/1

Robustness: It is the measure of the capacity of the analytical method to remain unaffected by small but deliberate variation in procedure. It provides an indication about variability of the method during normal laboratory conditions. (1,12)

MOLECULAR STRUCTURE OF DOLUTEGRAVIR

 

 

Molecular Formula

C20H19F2N3O5 (17,18)

Molecular Weight

419.45 g/mol (17)

IUPAC Name

(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido [1',2':4,5] pyrazino[2,1-b] [1,3] oxazine-9-carboxamide (17,18)

ChemSpider ID

25067956 (18)

Density

1.45 g/cm³ (18)

Boiling Point

998.8 °C (at 760 mmHg) (18)

Vapour Pressure

2.15 × 10^-9 Pa (at 25 °C) (18)

Flash Point

605.8 °C (18)

Refractive Index

1.63 (18)

Polar Surface Area

193.3 Ų (17)

LogP (Octanol/Water)

3.49 (17)

Generic Name

Dolutegravir (16)

Brand Names

Tivicay, Juluca (combination with rilpivirine) (20)

Drug Category

Antiretroviral, Integrase strand transfer inhibitor (INSTI) (16,19)

Indications

HIV-1 infection (treatment-naive and treatment-experienced adults and children) (19,20)

Pharmacology

Inhibits HIV-1 integrase, preventing viral DNA integration into host genome (16,19)

Potency

Highly potent, with IC50 values ranging from 0.05 to 0.5 nm (16)

Tolerability

Generally well-tolerated, with common adverse effects including insomnia, headache, and diarrhea (16,20)

Contraindications

Hypersensitivity to dolutegravir or any component of the formulation (20)

Adverse Effects

Common: insomnia, headache, diarrhea; Less common: hypersensitivity reactions, liver enzyme elevations (16,20)

Availability

Available in oral tablet and film-coated tablet formulations, as well as a powder for oral suspension (20)

MOLECULAR STRUCTURE OF RILPIVIRINE

 

 

 

Molecular Formula

C22H18N6 (22,23)

Molecular Weight

366.42 g/mol (22)

IUPAC Name

4-{[4-({4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl} amino) pyrimidin-2-yl] amino} benzonitrile (22,23)

ChemSpider ID

44457598 (23)

Density

1.23 g/cm3 (23)

Boiling Point

567.8 °C (1053.8 °F) (23)

Vapour Pressure

0.0 mmHg (20 °C) (23)

Flash Point

282.3 °C (540.1 °F) (23)

Refractive Index

1.65 (23)

Polar Surface Area

102.39 Å2 (22)

LogP (Octanol/Water)

4.45 (22)

Generic Name

Rilpivirine (21)

Brand Names

Edurant, Juluca (combination with dolutegravir) (24)

Drug Category

Antiretroviral, Non-nucleoside reverse transcriptase inhibitor (NNRTI) (21,25)

Indications

HIV-1 infection (treatment-naive and treatment-experienced adults and children) (24,25)

Pharmacology

Inhibits HIV-1 reverse transcriptase, preventing viral replication (21,25)

Potency

Highly potent, with IC50 values ranging from 0.27 to 0.34 Nm (21)

Tolerability

Generally well-tolerated, with common adverse effects including depression, insomnia, and rash (21,24)

Contraindications

Hypersensitivity to rilpivirine or any component of the formulation

Co-administration with proton pump inhibitors, rifampicin, rifapentine, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, St. John's Wort (24,25)

Adverse Effects

Common: depression, insomnia, rash

Less common: severe skin and hypersensitivity reactions, liver enzyme elevations (21,24)

Availability

Available in oral tablet formulation, 25 mg (24)

Mechanism of Action

1. Binds to HIV-1 reverse transcriptase (21)

2. Inhibits reverse transcription, preventing viral replication (21,25)

3. Prevents integration of viral DNA into host genome (21,25)

 

MATERIALS AND METHODS:

List of Proposed Materials:

 

S.

No.

Chemicals/standards and reagents

Grade

Make

Used for the estimation of drugs

1

Phosphate buffer

HPLC

Qualigens

1. Dolutegravir and Rilpivirine

2

Acetic acid

HPLC

Qualigens

1. Dolutegravir and Rilpivirine

3

Water

HPLC

Qualigens

For all drugs

4

Acetonitrile

HPLC

Qualigens

For all drugs

5

Methanol

HPLC

Rankem

For all drugs

Equipment’s and instruments used in the study:

S.No.

Equipment

Model/Type

Manufacturer

1

Electronic Balance

SAB2032

SCALETEC

2

Ultra-Sonicator

SE60US

LABMAN SCIENTIFIC INDIA

3

Thermal Oven

i-THERM A17782

DWARAKA SCIENTIFIC

4

pH Meter

ORION STAR A111

THERMOSCIENTIFIC

5

Filter Paper

0.45 microns

MILLIPORE

6

HPLC System

WATERS 2690 SEPARATION MODULE

WATERS

 

Optimization of Column: YMC ODS (4.6*250mm, 5µm) was found to be ideal as it gave good peak shape and resolution at 1.0 ml/min flow.

OPTIMIZED CHROMATOGRAPHIC CONDITIONS

Equipment                  :     High performance liquid chromatography equipped with                                                                         Auto Sampler and PDA detector

Column                       :           YMC ODS (4.6*250mm, 5µm)

Buffer                         :           Phosphate buffer

PH                                :          3.5

Mobile phase              :           35% buffer: 65% Methanol

Flow rate                     :           1.0 ml per min

Wavelength                :           250 nm

Injection volume         :           20 ml

Run time                     :           12 min.

S.No

Name

RT(min)

Area    (µV sec)

Height (µV)

Resolution

USP

tailing

USP     plate count

1

Dolutegravir

3.602

214546

8021578

4.57

1.06

4596

2

Rilpivirine

5.148

34475

124577

1.2

3153

 

System Suitability: Tailing factor for the peaks due to Dolutegravir and Rilpivirine in Standard solution should not be more than 2.0.  Theoretical plates for the Dolutegravir and Rilpivirine peaks in Standard solution should not be less than 2000

Calculation: (For Dolutegravir and Rilpivirine)

 

 

Where:

 AT      = average area counts of sample preparation.

 AS      = average area counts of standard preparation.

             WS     = Weight of working standard taken in mg.

  P        = Percentage purity of working standard

                                                                                                                                                                                LC       = Label Claim mg/ml.

Acceptance criteria of System Suitability:

  1. Tailing factor should be less than 2
  2. Theoretical Plates should be above 2000

RESULTS AND DISCUSSION

TRIAL - 1

Instrument used        : High performance liquid chromatography equipped  with Auto Sampler and PDA

Temperature               :            Ambient

Column                       : Platisil C18, (250×4.6mm, 5mm)

Mobile phase              :  65% Methanol: 35% NaH2PO4 PH-4

 Flow rate                    :           0.9 ml per min

Wavelength                :           250 nm

Injection volume         :           10 ml

Run time                     :           10 min.

TRAIL 2

Instrument used       :  High performance liquid chromatography equipped  with    Auto Sampler and     PDA

Temperature               :            Ambient

Column                       :           Spurcil C18, (250×4.6mm, 5mm)

Mobile phase              :           65% Methanol: 35% NaH2PO4 PH-4.5

 Flow rate                    :           0.8 ml per min

Wavelength                :           250 nm

Injection volume         :           10 ml

Run time                     :           10 min.

TRAIL 3

Instrument used : High performance liquid chromatography equipped with Auto Sampler and PDA

Temperature               :            Ambient

Column                       :           Inertsil, (250×4.6mm, 5mm)

Mobile phase              :           65% Methanol: 35% NaH2PO4 PH-4

 Flow rate                    :           0.9 ml per min

Wavelength                :           250 nm

Injection volume         :           10 ml

Run time                     :           10 min.

1 VALIDATION PARAMETERS:

1.1 ASSAY:

Standard and sample solution injected as described under experimental work. The corresponding chromatograms and results are shown below.

Figure 1: Chromatogram for Standard

Figure 2: Chromatogram for Sample

Table 1: Results of Assay for Dolutegravir and Rilpivirine

S.No

Name (STD)

RT(min)

Area

(µV sec)

Height (µV)

Resolution

USP

tailing

USP

plate count

1

Dolutegravir

3.608

12867

8021578

4.7

1.06

3246

2

Rilpivirine

5.148

34475

124577

1.08

68369

S.No

Name (Sample)

RT(min)

Area            (µV sec)

Height (µV)

5.01

USP

tailing

USP     plate count

1

Dolutegravir

3.608

214258

8021578

1.25

3465

2

Rilpivirine

 

5.148

33983

124577

1.06

6942

 

 

Label Claim

(mg)

 

% Assay

Dolutegravir

50 mg

99.6%

Rilpivirine

25mg

98.0%

 

2 LINEARITY:

The linearity range was found to lie from 10µg/ml to 50µg/ml of Dolutegravir and Rilpivirine and chromatograms are shown below.

Table 2:  Area of different concentration of Dolutegravir and Rilpivirine

S. No

Dolutegravir

Concentration (µg/ml)

Area

1

20

71596

2

40

143965

3

60

213269

4

80

275985

5

100

347416

 

S. No

Rilpivirine

Concentration (µg/ml)

Area

1

10

10786

2

20

21469

3

30

32652

4

40

42586

5

50

53512

Figure 3: Calibration graph for Dolutegravir

Figure 4: Calibration graph for Rilpivirine

Table 4: Analytical performance parameters of Dolutegravir and Rilpivirine

Parameters

Dolutegravir

Rilpivirine

Slope (m)

6913

534.49

Intercept (c)

2546.8

109.67

Correlation coefficient (R2)

0.9995

0.9998

Results of Precision for Dolutegravir and Rilpivirine

Injection

Dolutegravir Area

Rilpivirine Area

Injection-1

214652

33321

Injection-2

214985

33658

Injection-3

214423

33756

Injection-4

214145

33249

Injection-5

214021

33943

Injection-6

214362

33145

Average

214213

33397

Standard Deviation

214400.1

33495.57

%RSD

329.4786

293.9069

 

Table 5: Results for variation in mobile phase composition for Dolutegravir and

Rilpivirine

 

S. No

Change in Organic Composition in the Mobile Phase

System Suitability Results of Dolutegravir

USP Plate Count

USP Tailing

1

10% less(54ml)

3075

1.05

2

*Actual(60ml)

3069

1.08

3

10% more(66ml)

3053

1.02

 

 

S. No

Change in Organic Composition in the Mobile Phase

System Suitability Results of Rilpivirine

USP Plate Count

USP Tailing

1

10% less(54ml)

6947

1.04

2

*Actual(60ml)

6991

1.07

3

10% more(66ml)

6939

1.2

 

CONCLUSION

The developed RP-HPLC method is accurate, precise, linear, robust, and sensitive for the simultaneous determination of Dolutegravir and Rilpivirine. All validation parameters including system suitability, precision, accuracy, linearity, LOD, LOQ, and robustness were found to be within acceptable limits, confirming the suitability of the method for routine quality control analysis. The method is economical, time-efficient, and reproducible, making it highly suitable for regular laboratory use in pharmaceutical industries and research laboratories for the analysis of these drugs in combined dosage forms.

REFERENCES

  1. International Council for Harmonisation (ICH). ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. Geneva: ICH; 2005.
  2. International Council for Harmonisation (ICH). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
  3. United States Food and Drug Administration (FDA). Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics. Silver Spring (MD): FDA; 2015.
  4. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken (NJ): John Wiley & Sons; 2010.
  5. Skoog DA, Holler FJ, Crouch SR. Principles of Instrumental Analysis. 6th ed. Belmont (CA): Cengage Learning; 2007.
  6. Willard HH, Merritt LL, Dean JA, Settle FA. Instrumental Methods of Analysis. 7th ed. New Delhi: CBS Publishers; 2004.
  7. Chatwal GR, Anand SK. Instrumental Methods of Chemical Analysis. 5th ed. Mumbai: Himalaya Publishing House; 2002.
  8. Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry. 4th ed. New Delhi: CBS Publishers; 2007.
  9. United States Pharmacopeia (USP). USP 43–NF 38. Rockville (MD): United States Pharmacopeial Convention; 2020.
  10. European Medicines Agency (EMA). Guideline on Bioanalytical Method Validation. London: EMA; 2011.
  11. Kazakevich Y, Lobrutto R. HPLC for Pharmaceutical Scientists. Hoboken (NJ): John Wiley & Sons; 2007.
  12. Swartz ME, Krull IS. Analytical Method Development and Validation. New York: Marcel Dekker; 2012.
  13. Dong MW. Modern HPLC for Practicing Scientists. Hoboken (NJ): John Wiley & Sons; 2006.
  14. Meyer VR. Practical High-Performance Liquid Chromatography. 5th ed. Chichester: John Wiley & Sons; 2010.
  15. British Pharmacopoeia Commission. British Pharmacopoeia. London: The Stationery Office; 2020.
  16. DrugBank Online. Dolutegravir: drug information, mechanism of action, pharmacology and pharmacokinetics. Available from: https://go.drugbank.com
  17. PubChem Database. Dolutegravir; CID: 54726191. National Center for Biotechnology Information, U.S. National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov
  18. ChemSpider. Dolutegravir: chemical structure and physicochemical properties; ChemSpider ID: 25067956. Royal Society of Chemistry. Available from: http://www.chemspider.com
  19. World Health Organization (WHO). Dolutegravir (DTG): antiretroviral drug profile and clinical use in HIV treatment. Geneva: WHO; Available from: https://www.who.int

Reference

  1. International Council for Harmonisation (ICH). ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. Geneva: ICH; 2005.
  2. International Council for Harmonisation (ICH). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
  3. United States Food and Drug Administration (FDA). Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics. Silver Spring (MD): FDA; 2015.
  4. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken (NJ): John Wiley & Sons; 2010.
  5. Skoog DA, Holler FJ, Crouch SR. Principles of Instrumental Analysis. 6th ed. Belmont (CA): Cengage Learning; 2007.
  6. Willard HH, Merritt LL, Dean JA, Settle FA. Instrumental Methods of Analysis. 7th ed. New Delhi: CBS Publishers; 2004.
  7. Chatwal GR, Anand SK. Instrumental Methods of Chemical Analysis. 5th ed. Mumbai: Himalaya Publishing House; 2002.
  8. Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry. 4th ed. New Delhi: CBS Publishers; 2007.
  9. United States Pharmacopeia (USP). USP 43–NF 38. Rockville (MD): United States Pharmacopeial Convention; 2020.
  10. European Medicines Agency (EMA). Guideline on Bioanalytical Method Validation. London: EMA; 2011.
  11. Kazakevich Y, Lobrutto R. HPLC for Pharmaceutical Scientists. Hoboken (NJ): John Wiley & Sons; 2007.
  12. Swartz ME, Krull IS. Analytical Method Development and Validation. New York: Marcel Dekker; 2012.
  13. Dong MW. Modern HPLC for Practicing Scientists. Hoboken (NJ): John Wiley & Sons; 2006.
  14. Meyer VR. Practical High-Performance Liquid Chromatography. 5th ed. Chichester: John Wiley & Sons; 2010.
  15. British Pharmacopoeia Commission. British Pharmacopoeia. London: The Stationery Office; 2020.
  16. DrugBank Online. Dolutegravir: drug information, mechanism of action, pharmacology and pharmacokinetics. Available from: https://go.drugbank.com
  17. PubChem Database. Dolutegravir; CID: 54726191. National Center for Biotechnology Information, U.S. National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov
  18. ChemSpider. Dolutegravir: chemical structure and physicochemical properties; ChemSpider ID: 25067956. Royal Society of Chemistry. Available from: http://www.chemspider.com
  19. World Health Organization (WHO). Dolutegravir (DTG): antiretroviral drug profile and clinical use in HIV treatment. Geneva: WHO; Available from: https://www.who.int

Photo
Baswaraju Aruna
Corresponding author

Assistant Professor, Surabhi Dayakar Rao College of Pharmacy, Gajwel, Siddipet, Telangana

Photo
Macharla Rakesh
Co-author

Surabhi Dayakar Rao College of Pharmacy, Gajwel, Siddipet, Telangana.

Photo
Jarupla Abhishek
Co-author

Surabhi Dayakar Rao College of Pharmacy, Gajwel, Siddipet, Telangana.

Photo
Ulli Vaman Shiva
Co-author

Surabhi Dayakar Rao College of Pharmacy, Gajwel, Siddipet, Telangana.

Photo
Durgam Shashank
Co-author

Surabhi Dayakar Rao College of Pharmacy, Gajwel, Siddipet, Telangana.

Baswaraju Aruna, Macharla Rakesh, Jarupla Abhishek, Ulli Vaman Shiva, Durgam Shashank, Development and Validation of an HPLC Method for the Simultaneous Estimation of Dolutegravir and Rilpivirine in Bulk and Pharmaceutical Dosage Forms, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 6, 1344-1355, https://doi.org/10.5281/zenodo.20556264

Related Articles
Preparation, Evaluation and Antibacterial Assessment of Polyherbal Face Cream En...
Hiteksha Kajale, Dr. P. Sable, Arti Ingole, Sushant Surekar, Tanzila Pathan...
Formulation and Evaluation of Polyherbal Gastroprotective Suspention Using Bael ...
Snehal Kadam , Hrutuja Chavan , Sapana Waghmare , Chaitanya Damale, Shivam Limbore , Varad lad ...
Simultaneous Estimation of Amlodipine and Chlorthalidone in Combined Dosage Form...
Dr. Deepali Kadam , Dr. Laximikant Borse, Vaishnavi Rasal...